The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

On Friday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.44 which represents a decrease of $-0.45 or -23.81% from the prior close of $1.89. The stock opened at $1.75 and touched ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

Dec 12 (Reuters) - Editas Medicine (EDIT.O), opens new tab said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's ...

Editas Medicine (EDIT) announced a pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the company to accelerate its intent to achieve in vivo human proof of ...

Baird’s target price would suggest a potential upside of 455.56% from the company’s current price. A number of other analysts ...